- Press Releases
- UAE Ministry of Industry and Advanced Technology MoIAT Reviews Julphar state-of-the-art Insulin Production Facility in Ras Al Khaimah.
UAE Ministry of Industry and Advanced Technology MoIAT Reviews Julphar state-of-the-art Insulin Production Facility in Ras Al Khaimah.
A delegation from the Ministry of Industry and Advanced Technology (MoIAT), led by His Excellency Omar Ahmed Suwaina Al Suwaidi, Undersecretary of MoIAT, and His Excellency Abdullah Al Shamsi, Assistant Undersecretary for the Industrial Development Sector, has visited Gulf Pharmaceuticals Industries (Julphar), the leading pharmaceutical manufacture in the MENA region, to learn about the significant breakthroughs and the recent achievements in the healthcare sector that Julphar is witnessing, these include being recognized as one of the world’s largest producers of Raw Insulin material that Julphar’s state-of-the-art UAE-based biotechnology facility supports.
The delegation discusses various innovative industrial future collaborations, ensuring an environment that enhances the sector’s success based on the pillars of innovation, sustainability, and future foresight. The delegation was received by Dr. Essam Mohamed, Julphar CEO, alongside several Julphar senior executives.
The visit is part of the Ministry’s efforts to maintain strong, direct ties with its local partners in the priority national industrial sectors, including the health care sector. This outreach includes discussions on ways to provide additional facilities for projects that support partners’ strategic plans and enhance the UAE’s industrial sector in line with the UAE’s national strategy for industry and advanced technology.
During the visit to Julphar headquarter in the emirate of Ras Al Khaimah, H.E Omar Ahmed Al Suwaidi and his accompanying delegation were briefed on the recent achievements of the UAE-Based local manufacturer and its future strategic growth plans. Dr. Essam Mohamed, Julphar's CEO, outlined the company's business, expansion opportunities, the success of its turnaround program in only two years, and Julphar's mission to provide market-leading pharmaceutical products to local and international consumers. H.E also toured the headquarters of Julphar and visited the 12 state-of-the-art manufacturing facilities, including the Insulin manufacturing facility, the first of its kind facility in the MENA region that produces nearly 1,200kg/y of Insulin from API or around 40m vials of Insulin, which is enough to serve the region's total need of Insulin.
Enhancing the industrial sector competitiveness
His Excellency Omar Ahmed Suwaina Al-Suwaidi, Undersecretary of the Ministry of Industry and Advanced Technology (MoIAT) said, “Our field visits are an essential method to directly interact and discuss ways to enhance a supportive business environment for local and international industrial investors, in line with the objectives of the national strategy for industry and advanced technology, especially in terms of supporting the growth of national initiatives and enhancing their competitiveness in the markets, as a critical driver to enhance the UAE's position as a global destination for leading future industries.”
His Excellency said: We witnessed a remarkable development in the national pharmaceutical industries, and during the visit, we learned about a pioneering national model in the production of raw insulin, which reflects the strengthening of national capabilities in vital industries, such as the pharmaceutical sector comes among our top future priorities to focus on in cooperation with our partners, to achieve drug security. I invite investors to take advantage of the competitive advantages offered by the UAE to achieve growth in industrial projects. The UAE guarantees investors an industrial environment with international standards that cover infrastructure, logistics, the flexibility of laws, legislation, and standard specifications. It also provides competitive financing opportunities to encourage sustainable growth in the industrial sector, improving its performance and competitiveness.
Dr. Essam Mohammed, Julphar CEO, emphasized the efforts undertaken by the UAE leadership and His Excellency Dr. Sultan bin Ahmad Sultan Al Jaber, the UAE's Minister of Industry and Advanced Technology, towards further establishing the industrial sector's position, being a cornerstone of the economy and ensure an appealing industrial landscape and proposition for international investors, guaranteeing a sustainable future.
"It was an absolute honor to welcome H.E Omar Ahmed Al Suwaidi and the MoIAT delegation to Julphar. We are fully aligned with MoIAT's efforts to further enhance our national capacities with future-focused initiatives. We will remain committed to enhancing the UAE's economic competitiveness and status as a global hub for pioneering and innovative industries for the next 50 years." He added.
Julphar announced its Strategy 2030 to drive transformation through sustainable growth and deliver enhanced value for all stakeholders. The announcement came after the company completed one of the most remarkable turnaround stories in the region's pharma sector and marked a return to profit in 2021 with robust top-line growth.
It's worth mentioning that Julphar is one of the largest pharmaceutical companies in the Middle East and Africa. For more than four decades, the company has been delivering high-quality, innovative, and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 2,300 people and distributes pharmaceutical products to more than 50 countries across the globe, and operates 12 accredited manufacturing facilities in the emirate of Ras Al Khaimah, UAE.
Ras Al Khaimah is home to a thriving manufacturing and industrial sector, one of the strongest in the region, as the booming manufacturing sector contributes over a quarter of the Emirate’s GDP and forms a large proportion of its global exports. The emirate also offers critical drivers for an attractive investment environment, such as low business costs and resilient growth opportunities.